Program
cadonilimab
Also written as “AK104”, “Cadonilimab” and “Cadonilimab (AK104)”.
Its studies are mostly in Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms · Carcinoma, Renal Cell · Stomach Neoplasms, led by 4 companies.
Drug pageCadonilimab: every studyAll 173 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Akeso | 4219 open or running | phase 3since Jul 21, 2021 | Aug 20, 2017 | Nov 2026phase 3 · NCT06341335 |
| RemeGenits history only | 11 open or running | phase 3since Jan 15, 2024 | Jan 15, 2024 | Dec 2026phase 3 · NCT06221748 |
| Shanghai Pharmaceuticalsits history only | 11 open or running | phase 2since Jul 6, 2023 | Jul 6, 2023 | Dec 31, 2026phase 2 · NCT05944224 |
| Summit Therapeuticsits history only | 11 open or running | phase 2since Sep 29, 2026 | Sep 29, 2026 | Apr 12, 2029phase 2 · NCT07877194 |
Also a collaborator on its studies: Chipscreen Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Akeso only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 29 earlier studies, Aug 20, 2017 to Jun 27, 2023.
- Dec 19, 2020Named cadonilimabINNProposed as its International Nonproprietary Name in WHO's List 124 · before, AK104
- Aug 3, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05990127 · 642 planned · China
- Mar 26, 2024Phase 3 study in Gastric and Gastroesophageal Junction AdenocarcinomaNCT06341335 · 506 planned · China
- Apr 15, 2024Phase 3 study in Carcinoma, HepatocellularNCT06371157 · 469 planned · China
- Aug 15, 2024Phase 2 study in Ovarian NeoplasmsNCT06560112 · 172 planned · China
- Sep 25, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06617416 · 560 planned · China
- Oct 16, 2024Phase 2 study in Metastatic Pancreatic Ductal AdenocarcinomaNCT06646055 · 110 enrolled · China
- May 15, 2025Phase 2 study in Carcinoma, HepatocellularNCT06984718 · 120 planned
- Jun 10, 2025Phase 3 study in AdenocarcinomaNCT07023315 · 760 planned · China
- Nov 24, 2025Phase 2 study in Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaNCT07263919 · 90 planned · China
- Feb 9, 20262 phase 3 studiesNCT07412613, NCT07449780
- May 26, 2026Phase 1 study in Healthy Male Adults ParticipantsNCT07619001 · 158 planned · China
- Jul 8, 2026Phase 3 study in Stomach NeoplasmsNCT07700979 · 900 planned · United States, China, Germany and more
- Sep 28, 2026Phase 2 study terminatedStudy stoppedNCT05932212 · “Sponsor decision”
- Nov 12, 2026Primary completion moved from 2026-11-05 to 2028-06-30Date moved laterphase 1 · +20 months · NCT06929663
Ahead
- Nov 2026Primary completion: phase 3 study in Gastric and Gastroesophageal Junction AdenocarcinomaNCT06341335
- Nov 30, 2026Primary completion: phase 2 study in Carcinoma, HepatocellularNCT06984718
- Dec 30, 2026Primary completion: phase 2 study in Metastatic Pancreatic Ductal AdenocarcinomaNCT06646055
- Apr 2027Primary completion: phase 2 study in Advanced Solid TumorNCT05142423
TargetBeta
“A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor; Cytotoxic T-lymphocyte protein 4 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| lorigerlimabrule | MacroGenics | phase 2 | 4 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
Studies
All 42 Akeso leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07700979Stomach Neoplasms · United States, China, Germany and more | 3 | Recruiting | Aug 18, 2029 | 900 |
| NCT07619001Healthy Male Adults Participants · China | 1 | Not yet recruiting | Sep 30, 2026 | 158 |
| NCT07449780Gastric / Gastroesophageal Junction Adenocarcinoma | 3 | Not yet recruiting | Nov 17, 2027 | 422 |
| NCT07412613Resectable Colon Cancer · China | 3 | Recruiting | Jun 15, 2030 | 386 |
| NCT07263919Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma · China | 2 | Recruiting | Mar 2030 | 90 |
| NCT07023315Adenocarcinoma · China | 3 | Recruiting | Jul 2029 | 760 |
| NCT06984718Carcinoma, Hepatocellular | 2 | Not yet recruiting | Nov 30, 2026 | 120 |
| NCT06646055Metastatic Pancreatic Ductal Adenocarcinoma · China | 2 | Active, not recruiting | Dec 30, 2026 | 110 |
| NCT06617416Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Oct 28, 2026 | 560 |
| NCT06560112Ovarian Neoplasms · China | 2 | Recruiting | May 1, 2026 | 172 |
| NCT06371157Carcinoma, Hepatocellular · China | 3 | Recruiting | Oct 25, 2025 | 469 |
| NCT06341335Gastric and Gastroesophageal Junction Adenocarcinoma · China | 3 | Recruiting | Nov 2026 | 506 |
| NCT05990127Carcinoma, Non-Small-Cell Lung · China | 3 | Not yet recruiting | Aug 5, 2025 | 642 |
| NCT05932212Vulvar Neoplasms · China | 2 | Terminated | May 31, 2026 | 20 |
| NCT05904379Advanced Non-small-cell Lung Cancer · China | 2 | Active, not recruiting | Jun 30, 2026 | 233 |
| NCT05559554Healthy Male Subjects · China | 1 | Completed | Mar 24, 2023 | 100 |
| NCT05559541Solid Tumor, Adult · China | 2 | Terminated | May 31, 2024 | 33 |
| NCT05505825SCLC,Extensive Stage · Australia, China | 2 | Completed | Jul 19, 2024 | 36 |
| NCT05489289Carcinoma, Hepatocellular · China | 3 | Recruiting | Jan 28, 2026 | 570 |
| NCT05319431Unresectable, Non-metastatic Hepatocellular Carcinoma · China | 2 | Active, not recruiting | Aug 15, 2023 | 60 |
| NCT05227651Uterine Cervical Neoplasms · China | 2 | Completed | Sep 27, 2024 | 14 |
| NCT05235542Advanced Malignant Tumors · China | 2 | Completed | May 9, 2026 | 128 |
| NCT05256472Carcinoma, Renal Cell · China | 2 | Completed | Dec 31, 2025 | 28 |
| NCT05235516Locally Advanced Cervical Carcinoma · China | 3 | Active, not recruiting | May 2026 | 636 |
| NCT05215067Advanced Non-small Cell Lung Cancer · China | 2 | Completed | Jan 30, 2026 | 44 |
| NCT05142423Advanced Solid Tumor · China | 2 | Recruiting | Apr 2027 | 198 |
| NCT05021120Advanced or Metastatic Solid Tumours · Australia | Early 1 | Completed | Oct 1, 2024 | 67 |
| NCT05008783Gastric Adenocarcinoma · China | 3 | Completed | Dec 6, 2024 | 610 |
| NCT04982237Uterine Cervical Neoplasms · China | 3 | Active, not recruiting | Dec 30, 2025 | 445 |
| NCT04868708Recurrence · China | 2 | Completed | Feb 28, 2024 | 50 |
| NCT04728321Carcinoma, Hepatocellular · China | 2 | Completed | Aug 2, 2022 | 32 |
| NCT04646330NSCLC · China | 2 | Completed | Oct 26, 2023 | 114 |
| NCT04647344Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV · China | 2 | Completed | Dec 31, 2023 | 46 |
| NCT04572152Advanced or Metastatic Solid Tumors · Australia | 1 | Completed | May 2, 2023 | 23 |
| NCT04547101MSI-H/dMMR Solid Tumor · China | 2 | Terminated | Sep 30, 2022 | 6 |
| NCT04444167Carcinoma, Hepatocellular · China | 2 | Completed | Nov 20, 2023 | 59 |
| NCT04444141Lymphoma, T-Cell, Peripheral · China | 2 | Terminated | Sep 30, 2022 | 6 |
| NCT04380805Uterine Cervical Neoplasms · United States, Australia, New Zealand | 2 | Completed | Dec 22, 2022 | 30 |
| NCT04220307Nasopharyngeal Carcinoma · China | 2 | Completed | May 15, 2021 | 34 |
| NCT04172454Melanoma · China | 2 | Completed | Jun 17, 2021 | 68 |
| NCT03852251Diabetes Mellitus, Insulin-Dependent, 12 · China | 2 | Completed | Mar 25, 2024 | 338 |
| NCT03261011Advanced Cancer · Australia | 1 | Completed | Aug 27, 2021 | 119 |
How it is read
Names in the registry
- “AK104”, 26 entries
- “Cadonilimab”, 3 entries
- “Cadonilimab (AK104)”, 3 entries
- “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
- “AK104+anlotinib”, 3 entries
Codes read as this program: AK104.
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 6 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Uterine Cervical Neoplasms, 4 studies
- Carcinoma, Renal Cell, 2 studies
- Stomach Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.